Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Neurocrine Biosciences's NBI-1117568?
NBI-1117568 is a small molecule commercialized by Neurocrine Biosciences, with a leading Phase II program in Schizophrenia. According to Globaldata,...
Data Insights
Risk adjusted net present value: What is the current valuation of Neurocrine Biosciences's NBI-1117568?
NBI-1117568 is a small molecule commercialized by Neurocrine Biosciences, with a leading Phase II program in Schizophrenia. According to Globaldata,...